ArticleDrugs in context2024

Nivolumab plus ipilimumab with chemotherapy in metastatic NSCLC: minireview and a case study of a patient negative for PD-L1.

Alessandro MorabitoPubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.